Latest Breaking News On - Global coordinators - Page 32 : comparemela.com

Hexagon Purus ASA: Contemplated Private Placement

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE

United statesHong kongDistrict of columbiaBritish columbiaJon erik engesetMorten holumSkandinaviska enskilda bankenAdvokatfirmaet schjDilip warrierMathias meidellSalman alamNeither the companyCorporate developmentCompany the offerUnited states exchangeCompany board of directors the

Aelis Farma, a biopharmaceutical company developing a new generation of drugs for brain diseases, announces the success of its initial public offering and raises approximately €25 million on Euronext Paris

Capital increase of approximately €25 million, i.e. 100% of the initial objective, despite high market volatility Size of the transaction which may be increased to approximately €25.55 million

United statesUnited kingdomBpifrance financementKostenloser wertpapierhandelNicolas merigeauVincenzo piazzaInserm magendie neurocentreDaelis farmaIndivior united kingdom ltdInserm transfert initiativeEuropean parliamentUnited kingdom financial conduct authorityNeurology of the french academy sciencesFinancial servicesEuropean union withdrawalCommission delegated directive

Aelis Farma, a Biopharmaceutical Company Developing a New Generation of Drugs for Brain Diseases, Launches Its Initial Public Offering on the Regulated Market of Euronext Paris

02.02.2022 - Regulatory News: Not to be distributed, directly or indirectly, in the United States of America, Canada, Australia, Japan or South Africa. Aelis Farma, a clinical-stage biopharmaceutical company specializing in the development of treatments for .

United statesFrance generalUnited kingdomSouth africaComunidad autonoma de catalunaVincenzo piazzaInserm magendie neurocentreDaelis farmaFrances levinEuropean councilNational institute of healthUnited kingdom financial conduct authorityNeurology of the french academy sciencesEuropean union withdrawalEuropean unionCommission delegated directive

Aelis Farma, a Biopharmaceutical Company Developing a New Generation of Drugs for Brain Diseases, Launches Its Initial Public Offering on the Regulated Market of Euronext Paris

Capital increase of €25 million, which may be increased to a maximum of approximately €33 million in the event the Extension Clause and the Over-Allotment Option are fully exercised Irrevocable

United statesFrance generalUnited kingdomSouth africaComunidad autonoma de catalunaKostenloser wertpapierhandelNicolas merigeauVincenzo piazzaInserm magendie neurocentreDaelis farmaFrances levinEuropean councilNational institute of healthUnited kingdom financial conduct authorityNeurology of the french academy sciencesEuropean union withdrawal

JCDecaux successfully placed 8-year notes for a principal amount of €500 million

JCDecaux successfully placed 8-year notes for a principal amount of €500 million
padovanews.it - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from padovanews.it Daily Mail and Mail on Sunday newspapers.

United statesFrance generalEuronext parisGlobal coordinatorsHome mediaEurolistof euronext parisEuronext family businessOut of home mediaLatin americaMiddle eastAlbert ass